Eli Lilly   The FDA extended its review for Eli Lilly (LLY) oral obesity drug, orforglipron, pushing the target decision date to April 10, 2026, from earlier expectations of late March, despite it receiving a Commissioner's National Priority Voucher for faster . . . This content is for paid subscribers. Please click here to subscribe or here to log in.